2-(2-acetamido-3,5-dihydroxyphenoxy)-5-aminobenzoic acid | 1221230-64-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-acetamido-3,5-dihydroxyphenoxy)-5-aminobenzoic acid
• CAS: 1221230-64-3
• 化学式: C₁₅H₁₄N₂O₆
• 分子量: 318.286
• InChiKey: MNNXSQXQMMHHJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  142
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(2-acetamido-3,5-dihydroxyphenoxy)-5-aminobenzoic acid 、 对氟苯甲酰氯 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 生成 2-(2-Acetamido-3,5-dihydroxyphenoxy)-5-[(4-fluorobenzoyl)amino]benzoic acid
  参考文献：
  名称：

  [EN] NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN
  [FR] NOUVEAUX INHIBITEURS POUR TRAITER DES MALADIES ASSOCIÉES À UN TRANSPORT EXCESSIF DE HYALURONANE

  摘要：

  公开号：

  WO2010066909A3
• 作为产物：
  描述：

  2-(2-acetamido-3,5-dihydroxyphenoxy)-5-nitrobenzoic acid 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 生成 2-(2-acetamido-3,5-dihydroxyphenoxy)-5-aminobenzoic acid
  参考文献：
  名称：

  [EN] COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING
  [FR] COMPOSÉS AYANT UNE ACTIVITÉ DE CORRECTION DU TRAITEMENT CELLULAIRE DU CFTR MUTANT

  摘要：

  公开号：

  WO2010066912A4

文献信息

• NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN
  申请人：Prehm Peter

  公开号：US20110245335A1

  公开（公告）日：2011-10-06

  The present invention relates in general to a compound which is characterized by a formula selected from the following formulas A, B, C, D, E or F; or a pharmaceutically acceptable salt thereof. The present invention further relates to pharmaceutical composition comprising the inhibitor(s) of the invention and to their use in the treatment of (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer. The present invention furthermore relates to the use of at least one inhibitor of the invention for the preparation of a pharmaceutical composition for the treatment of (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer. The present invention also relates to a method for manufacturing a pharmaceutical composition comprising the steps of formulating the inhibitor defined herein in a pharmaceutically acceptable form.

  本发明一般涉及一种化合物，其具有从以下公式A、B、C、D、E或F中选择的公式，或其药学上可接受的盐的特征。本发明还涉及包含本发明的抑制剂的制药组合物，并将其用于治疗与透过脂质双层的透明质酸过量转运相关的疾病。本发明还涉及使用本发明的至少一种抑制剂制备用于治疗与透过脂质双层的透明质酸过量转运相关的疾病的制药组合物的方法。本发明还涉及制造药学上可接受形式中定义的抑制剂的制药组合物的方法。
• COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING
  申请人：Universitätsklinikum Münster

  公开号：EP2376429A2

  公开（公告）日：2011-10-19
• NEW ACTIVATORS FOR TREATING AND/OR PREVENTING DISEASES OR MEDICAL CONDITIONS WHICH BENEFIT FROM AN INCREASED TRANSPORT OF HYALURONAN ACROSS A LIPID BILAYER
  申请人：Prehm Peter

  公开号：US20110245192A1

  公开（公告）日：2011-10-06

  The present invention relates in general to a compound (activator) which is characterized by a formula selected from the following formulas A, B and/or C or a pharmaceutically acceptable salt thereof. The present invention further relates to pharmaceutical composition comprising the activator(s) of the invention and to their use in the treatment of (for treating) and/or preventing diseases or medical conditions which benefit from an increased transport of hyaluronan across a lipid bilayer. The present invention also relates to a method for manufacturing a pharmaceutical composition comprising the steps of formulating the activator defined herein in a pharmaceutically acceptable form.
• [EN] NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN<br/>[FR] NOUVEAUX INHIBITEURS POUR TRAITER DES MALADIES ASSOCIÉES À UN TRANSPORT EXCESSIF DE HYALURONANE
  申请人：UNIVERSITAETSKLINIKUM MUENSTER

  公开号：WO2010066909A3

  公开（公告）日：2010-08-05
• [EN] COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING<br/>[FR] COMPOSÉS AYANT UNE ACTIVITÉ DE CORRECTION DU TRAITEMENT CELLULAIRE DU CFTR MUTANT
  申请人：UNIVERSITAETSKLINIKUM MUENSTER

  公开号：WO2010066912A4

  公开（公告）日：2010-10-14